



# Corporate Information

## Board of Directors

**Mr. Mayank S. Mehta**

Chairman and Independent Director

**Mr. S. N. Kamath**

Managing Director

**Mr. Gautam R. Ashra**

Non-Executive Director

**Dr. Vibha Gagan Sharma**

Whole-Time Director

**Mrs. Shruti Vishal Rao**

Whole-Time Director

**Mr. S. R. Vaidya**

Independent Director

**Mr. Santosh Parab**

Independent Director

## Registered Office

102, Hyde Park, Saki Vihar Road,  
Andheri (East), Mumbai - 400 072.

Phone No.: +91-22-42160000

Fax No.: +91-22-28563930

E-Mail: [info@blissgvs.com](mailto:info@blissgvs.com)

Website: [www.blissgvs.com](http://www.blissgvs.com)

## Registrar And Share Transfer Agent

Universal Capital Securities Pvt. Ltd.

21, Shakeel Niwas, Mahakali Caves Road,  
Andheri (East), Mumbai - 400 093.

Phone No.: +91-22-28366620

## Bankers

The Federal Bank Ltd

Export Import Bank of India

## Auditors

Kalyaniwalla & Mistry LLP

## Manufacturing Units

Plot No.: 10, 11 & 12,

Village: Aliyali, Palghar Taluka, Dist. Thane,  
Maharashtra - 401 404.

## Research & Development Centre

Unit 6, Hyde Park, Saki Vihar Road,  
Andheri (East), Mumbai - 400 072

# Contents



## Overview

Expanding Horizons	2
Key Milestones	3
Geographical Presence	4
Manufacturing Facilities	5
Business Overview	6
Research and Development	8
Consolidated Financial Highlights	9
Board of Directors	10
Managing Director's Message to Shareholders	11

## Statutory Section

Notice	12
Directors' Report	32
Management Discussion and Analysis	58
Corporate Governance	62
CEO/CFO Certificate	79

## Financial Section

Independent Auditor's Report	80
Standalone Balance Sheet	86
Standalone Statement of Profit and Loss	87
Standalone Cash Flow Statement	89
Significant Accounting Policies and Notes to Accounts	91
Consolidated Financial Statements	124

## A collage of medical and health-related icons and images. It includes a globe with network lines, a syringe, a pill bottle, a test tube, a microscope, a DNA helix, a family walking in a park, and various medical supplies like gloves, pills, and bottles.

Incorporated in 1984, Bliss GVS Pharma Limited (BGPL) is a pharmaceutical company engaged in the manufacturing, marketing and exporting of 250+ branded formulations in various dosage forms with major focus on the sub-Sahara African Region. The company's products cater to various therapeutic categories including Anti-fungal, Contraceptive, Laxative, Anti-haemorrhoidal, Anti-spasmodic, Antimalarial, Anti-biotic, Anti-microbial, Anti-inflammatory, Antipyretic, Analgesic and several others.

BGPL is continually seeking to evolve so that it is better able to serve the patients, improving all aspects of health care. The drive to continuously improve and expand is demonstrated by its unceasing foray into new dosage forms, therapeutic areas and geographies, while also firmly

establishing its capabilities as the world  
leaders in suppositories and pessaries.

Over the years, BGPL has further diversified its suppositories business by providing contract manufacturing services to leading pharmaceutical companies. The company is the contract manufacturer of choice for these leading international and domestic brands over the last decade due to its high quality systems.


Research & Development now forms the backbone of BGPL, offering it a competitive edge that is hard to beat. The company is continually seeking to expand its product portfolio as is evident by the constant focus on R&D. Providing quality medicines to the patients through constant improvements has been the success mantra for the company which is evident by the portfolio of trusted brands

that the company has built worldwide over the last three decades.

The company is well placed to further strengthen its position as a leading pharmaceutical company in sub-Saharan Africa which has consistently been one of the fastest growing markets. The company is on a voyage to strengthen its position in the sub-Saharan African region and also expand its presence in economies such as South-East Asia, US and Russia to cement its position as a trusted brand in the global pharmaceutical industry.

Major boost is expected from the new state-of-the-art facility in Palghar East, which has been designed to comply with the highest quality standards and cutting-edge technologies. BGPL strives to create a bigger impact by providing life-saving medicines across the world.

# Key Milestones




# Geographical Presence

BGPL is committed to improving the quality of life globally and is currently on an expedition to grow its presence in the sub-Saharan Africa, South East Asian markets and other countries such

as the US, UK and Russia. Currently, the company has a presence in more than 64 countries with major concentration on the sub-Saharan African region. The company has expertise in serving these

diverse geographies for more than 30 years and delivering quality products which add value to its customers.



## Africa

Angola  
Benin  
Botswana  
Burkina Faso  
Burundi  
Cameroon  
Central African Republic  
Chad  
Cote d'Ivoire  
Dem. Rep. Congo  
Ethiopia  
Gabon  
Gambia  
Ghana  
Guinea

Kenya  
Lesotho  
Liberia  
Libya  
Malawi  
Mali  
Mauretania  
Mauritius  
Mozambique  
Namibia  
Niger  
Nigeria  
Rep. of Congo  
Rwanda  
Senegal  
Sierra Leone  
South Sudan

Sudan  
Tanzania  
Togo  
Uganda  
Zambia  
Zimbabwe

## Asia

Afghanistan  
Bhutan  
India  
Macau  
Nepal

## CIS

Kazakhstan  
Kyrgistan

Tajikistan  
Turkmenistan  
Uzbekistan  
Russia (PE)

## Europe

France  
Romania  
United Kingdom  
Latvia (PE)  
Netherlands (PE)  
Portugal (PE)

## Middle East

Iraq  
Jordan  
Lebanon

Qatar  
UAE  
Yemen

## Central America

Costa Rica  
Guatemala  
Honduras  
Panama

## North America

Canada  
USA

## Oceania

Fiji  
New Zealand

Pap. New Guinea  
Australia (PE)

## South East Asia

Bangladesh  
Cambodia  
Hong Kong  
Laos  
Malaysia  
Maldives  
Sri Lanka  
Myanmar (OO)  
Philippines (OO)  
Singapore (RO)  
Vietnam (RO)

# Manufacturing Facilities

Currently, BGPL has 4 manufacturing facilities, which are certified by WHO-GMP, EU-GMP, ISO 14001 and OHSAS 45001.

Unit  
**1**

## Palghar (WHO-GMP)

Suppositories & Pessaries



**55 Mn**  
units/annum

Tablets



**300 Mn**  
units/annum

Dry Syrups



**6 Mn**  
units/annum

## Palghar (EU-GMP (PIC/S approval, WHO-GMP approved))

Suppositories & Pessaries



**200 Mn**  
units/annum

Unit  
**2**

Unit  
**3**

## Palghar (WHO-GMP Certified)

Suppositories & Pessaries



**400 Mn**  
units/annum

Sachets



**21.6 Mn**  
units/annum

## Ambernath (WHO-GMP Approved)

Ointments



Creams



Gels



**7.5 Mn**  
tubes/annum

Unit  
**4**



## Vevoor Plant

During the financial year, BGPL has setup another state of the art manufacturing facility in Palghar, Maharashtra having a total area of 19,000 sq. m. to increase the production capacities and cater to the South East Asian market and US, UK and Russia. The plant will be fully equipped to manufacture Tablets, Capsules, Dry Syrups, Ointments, and Sachets.

Moreover, a solar power plant has been deployed within the premises of the plant which will accommodate 30% of the energy requirements resulting in cost savings.

# Business Overview

BGPL has a leadership position in Anti-Malarial, Anti-Fungal Dermatological, Anti-Inflammatory branded formulations across sub-Saharan African markets with brands such as Lonart, P-Alaxin, Funbact, and Lofnac, etc, which are supplied in various dosage forms – tablets, suspensions, suppositories, and injections.



## Brand Leaders in Anti-Malarials

BGPL is a leading player in the anti-malarial branded formulations segment, which is a prized opportunity given the percentage of malaria cases in the African continent stands at ~90% of the global cases of malaria. BGPL's anti-malaria brands Lonart, P-Alaxin are leaders in their segments across east and west of Africa.

## Key Achievements in Anti-Malarial Segment

### Pioneers to offer Artesunate across two dosage forms

Injections 30/60/120 mg  
Suppositories 50/100/200 mg

### Pioneers in launching

6 dose Artemether +  
Lumefantrine combination  
with "Lonart DS"

### First to introduce

Dihydroartemisinin +  
Piperaquine combination  
suspension with "P-Alaxin  
Suspension"

### Pioneers in launching

Dihydroartemisinin +  
Piperaquine triple strength  
combination with "P-Alaxin  
TS Tabs"

## Key Brands in Cream and Ointment Segment

Funbact - A



Lofnac gel



## Therapeutic Segments and Dosage Forms



Over the past three decades, the company has developed an expertise in formulation development of branded generic products for international and domestic markets. BGPL's branded product portfolio comprises of 250+ products across 20+ therapeutic areas and 16+ dosage forms.

The company holds a strong position in various therapeutic segments like antimalarial, anti-fungal, anti-bacterial, anti-inflammatory products, with expertise in dosage forms of tablets, suppositories, suspensions and injectables.



## Pioneers & Leaders in Suppositories & Pessaries

BGPL is the world leader in Suppositories and Pessaries dosage forms with one of the largest product portfolios in this segment and has developed a niche expertise in this dosage form. The company is the only EU-GMP certified suppository and pessary manufacturer across India.

The major application of suppositories is in the medical field of Paediatrics, Geriatrics, and Gynaecology, and this dosage is widely used across countries

like UK, US, Russia, Japan and Africa for the treatment of inflammation, fungal infection, bacterial infection, constipation, contraceptive application and malaria etc. This dosage form has tremendous potential in countries with an ageing population.

Further, the 100 mg Rectal Artesunate Suppository is classified as pre-referral treatment according to the World Health Organisation for management of severe cases of malaria for children.

The company's brand under the name 'Gsunate' was launched to cater to this segment in the sub-Saharan African region.

The product portfolio of BGPL in the suppository dosage form extends to the therapeutic segments of Anti-malarial, Anti-haemorrhoidal, Laxative, Anti-inflammatory, Anti-emetic, Anti-depressant, etc.



# Research And Development

To boost growth in this rapid and fast-growing environment, Research & Development serves as a crucial part seeking knowledge to develop, design, and enhance products in every pharmaceutical company. The R&D centre based in Mumbai is fully integrated

with modern instruments like Particle Size Analyzer, Gas Chromatography, High-Performance Liquid Chromatography, Dissolution Tester, Stability Chambers, and Lab Scale Manufacturing machines.

BGPL's vision to improve the quality of life is taken further by the experienced R&D

team comprising of more than 100 highly qualified scientists and researchers. The R&D center is certified by the Department of Scientific & Industrial Research (DSIR), Government of India and consistently follows Good Laboratory Practice guidelines.

## R&D Integrated Services



Commercial Batches  
& Manufacturing



Pre-formulation  
development



Product Development



Stability Studies  
& Document  
Development



BE studies and Clinical  
end point studies